Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Ontology highlight
ABSTRACT: This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of rilotumumab or ganitumab in combination with panitumumab versus panitumumab alone in patients with metastatic colorectal cancer whose tumors are wild-type KRAS status.
DISEASE(S): Metastatic Colorectal Cancer,Rectal Neoplasms,Gastrointestinal Neoplasms,Colon Cancer,Gastrointestinal Cancer,Colorectal Cancer,Wild-type Kras Metastatic Colorectal Cancer.---------------------------------------------------------cáncer Colorrectal Metastásico Con Kras No Mutado,Colorectal Neoplasms,Rectal Cancer,Colonic Neoplasms
PROVIDER: 2063797 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA